Afalon Pharma Extends 50M Riyal Credit with Al-Inma

Al Nahda Pharma Company (Avallon Pharma) announced that it has renewed its credit facilities agreement with Alinma Bank worth 50 million Saudi Riyals. These facilities aim to support working capital and capital expenditures to ensure business continuity and future expansion. The financing term is one year, starting from mid-August 2026, with a promissory note equivalent to the financing amount provided as collateral. The company confirmed that there are no related parties involved in the agreement, which reinforces transparency and financial sustainability within its strategy to grow the pharmaceutical sector in Saudi Arabia.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل